Actinium: Clinical Trials

4 trials of Actinium, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 suspended, 1 not yet recruiting, 1 recruiting. 4 Phase 1, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 14Suspended 2, Not yet recruiting 1, Recruiting 1
Phase 21Recruiting 1

Follow Actinium: new trials by email Literature Review of Actinium trials Research Report on Actinium

Trials (filtered) newest first · largest first

All 4 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Testing the Combination of Anti-cancer Drugs Actimab-A and Cemiplimab (REGN2810) to Improve Outcomes for Patients With Recurrent Glioblastoma
Actinium Ac 225 Lintuzumab, Biospecimen Collection, Cemiplimab - Recurrent Glioblastoma, IDH-Wildtype, Recurrent Gliosarcoma
Phase 1Not yet recruitingNational Cancer Institute (NCI)302026-12-042026-06-12
Testing the Combination of Targeted Radiotherapy With Anti-Cancer Drugs, Venetoclax and ASTX-727, to Improve Outcomes for Adults With Newly Diagnosed Acute Myeloid Leukemia
Actinium Ac 225 Lintuzumab, Biospecimen Collection, Bone Marrow Aspiration - Acute Myeloid Leukemia
Phase 1SuspendedNational Cancer Institute (NCI)532026-11-182026-08-24
Testing an Anti-cancer Radio-Active Immunotherapy Called Lintuzumab Ac225 in Patients With High-Risk Myelodysplastic Syndrome That Has Not Responded to Other Treatment
Actinium Ac 225 Lintuzumab, Bone Marrow Aspiration, Buccal Swab - Refractory Myelodysplastic Syndrome
Phase 1SuspendedNational Cancer Institute (NCI)182026-09-032026-09-09
ACTinium in Castrate-RESistant Prostate Cancer After LUTEtium
Actinium (225Ac) rhPSMA-10.1 - Metastatic Castration-resistant Prostate Cancer, Metastatic Prostate Cancer
Phase 1 / Phase 2RecruitingUniversity College, London602026-04-132026-05-08

Conditions studied

Glioblastoma (1)  ·  Gliosarcoma (1)  ·  Leukemia, Myeloid, Acute (1)  ·  Myelodysplastic Syndromes (1)  ·  Prostatic Neoplasms (1)

Sponsors

National Cancer Institute (NCI) (3)  ·  University College, London (1)

Countries

United States (2)  ·  United Kingdom (1)

Top investigators

Gerhardt Attard (1)  ·  Manu Pandey (1)  ·  Megan Mantica (1)  ·  Talha Badar (1)

NIH funding

UM1CA186689 (1), UM1CA186690 (1), UM1CA186709 (1)